Soligenix (SNGX) AI Stock Analysis

• Market Cap: $6.17M
• Dividend Yield: N/A
• Average Volume (3M): 21.39K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.83
• Revenue Growth: N/A
• EPS Growth: 57.83%
• Country: US
• Employees: 14
• Sector: Healthcare
• Sector Strength: 55
• Industry: Biotechnology
• EPS (TTM): -1.06
• Shares Outstanding: 3,264,346
• 10 Day Avg. Volume: 25,996
• 30 Day Avg. Volume: 21,388
• PEG Ratio: 0.11
• Price to Book (P/B): 19.28
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -3.73
• Enterprise Value/Market Cap: 3.70
• Enterprise Value/Revenue: 13.54
• Enterprise Value/Gross Profit: -14.36K
• Enterprise Value/Ebitda: -0.69
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 39 Underperform
• Price Target: ―

Soligenix's overall stock score is primarily driven by its weak financial performance, characterized by declining revenues and persistent losses. While the technical analysis indicates some potential for short-term stability, the valuation and financial metrics suggest ongoing challenges. The company's recent loan repayment is a positive step towards financial flexibility, but it does not alleviate the underlying financial and operational issues.

Soligenix Business Overview & Revenue Model

Company Description

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates in two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of treat cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer. This segment also offers proprietary formulations of oral beclomethasone 17,21-dipropionate for the prevention/treatment of gastrointestinal disorders characterized by severe inflammation, including SGX203 for pediatric Crohn's disease; and SGX302 that is in Phase I/II clinical trial for the treatment of mild-to-moderate psoriasis. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia and Ib clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate in pre-clinical development for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.

How the Company Makes Money

Soligenix makes money primarily through the research, development, and commercialization of its biopharmaceutical products. The company's revenue streams include government grants and contracts, especially for its biodefense programs, as well as potential future revenues from product sales, partnerships, and collaborations with other pharmaceutical companies. Soligenix's financial success is heavily dependent on the successful development and approval of its lead product candidates, which can result in licensing agreements, milestone payments, and royalties. Additionally, its biodefense division benefits from government funding, which supports the development of vaccines and therapeutics for potential bioterrorism threats.

Soligenix Financial Statement Overview

Summary

Soligenix's financial health is concerning, with significant revenue decline, ongoing net losses, and high reliance on external financing. The company faces operational inefficiencies, evident in its negative margins and cash flow challenges. Despite efforts to secure financing, sustainability remains questionable without improvements in revenue and profitability.

Income Statement

Soligenix has experienced significant revenue decline over recent years, with a sharp drop from $4.6M in 2019 to just $119k in 2024. The net profit margin remains deeply negative, with a net loss of $8.7M in 2024. Both EBIT and EBITDA margins are negative, indicating ongoing operational challenges and inefficiencies in cost management. Revenue growth has also been inconsistent, reflecting volatility in business operations.

Balance Sheet

The company's balance sheet shows high financial leverage, with a debt-to-equity ratio fluctuating due to negative equity in some years. In 2024, the equity ratio improved slightly but still indicates reliance on debt financing. Return on equity remains negative due to continued net losses. Total assets have decreased significantly since 2019, reflecting a reduction in company scale and potentially diminishing asset utility.

Cash Flow

Soligenix's cash flow statements highlight consistent negative operating cash flow, indicating challenges in generating cash from core operations. Despite this, financing activities have periodically provided cash infusions, such as in 2024 with $7.7M from financing. Free cash flow remains negative, suggesting persistent cash outflows exceeding cash inflows from operations and investments.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
119.37K	839.36K	948.91K	824.27K	2.36M
	Gross Profit
-125.00K	97.31K	398.09K	95.63K	538.50K
	EBIT
-9.44M	-7.70M	-14.24M	-13.10M	-18.59M
	EBITDA
-8.64M	-7.85M	-14.11M	-12.48M	-18.45M
	Net Income Common Stockholders
-8.68M	-6.14M	-13.80M	-12.55M	-17.69M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
7.82M	8.45M	13.36M	26.04M	18.68M
	Total Assets
8.97M	9.80M	14.28M	26.87M	19.89M
	Total Debt
1.48M	3.49M	10.24M	9.96M	10.51M
	Net Debt
-6.33M	-4.95M	-3.12M	-16.08M	-8.17M
	Total Liabilities
4.85M	7.27M	16.75M	16.15M	16.15M
	Stockholders Equity
4.12M	2.52M	-2.47M	10.72M	3.74M
Cash Flow		Free Cash Flow
-8.40M	-8.60M	-12.66M	-11.75M	-11.46M
	Operating Cash Flow
-8.40M	-8.60M	-12.65M	-11.74M	-11.45M
	Investing Cash Flow
0.00	0.00	-13.07K	-11.79K	-7.15K
	Financing Cash Flow
7.76M	3.66M	76.82K	19.06M	24.68M

Soligenix Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.84
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SNGX, the sentiment is Negative. The current price of 1.84 is below the 20-day moving average (MA) of 1.89, below the 50-day MA of 1.95, and below the 200-day MA of 2.82, indicating a bearish trend. The MACD of -0.03 indicates Negative momentum. The RSI at 43.94 is Neutral, neither overbought nor oversold. The STOCH value of 30.14 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SNGX.

Soligenix Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	54 Neutral	$5.38B	3.31	-45.11%	3.29%	16.82%	0.04%
EVGN	47 Neutral	$12.08M	―	-655.00%	―	-26.38%	40.99%
APLM	42 Neutral	$7.52M	―	-233.67%	―	―	-1786.46%
SNGX	39 Underperform	$6.17M	―	-437.73%	―	―	57.83%
SLXN	34 Underperform	$8.17M	―	-590.37%	―	―	-73095.97%
MTVA	33 Underperform	$14.74M	―	-339.64%	―	―	-75.88%
OCEA		$1.91M	―		―	―	―

Soligenix Corporate Events

Soligenix Repays Loan, Boosting Financial Flexibility

On February 5, 2025, Soligenix, Inc. fully repaid and terminated its Loan and Security Agreement with Pontifax Medison Finance, eliminating all outstanding obligations and associated liens without incurring any prepayment penalties. This move reflects the company’s financial stability and strengthens its operational flexibility, potentially enhancing its position in the biopharmaceutical industry.